Place of Intrathecal CXCL-13 in the Diagnosis of Lyme Neuroborreliosis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05625100

Acronym

CXCL13-LYME

Enrollment

141

Registered

2022-11-22

Start date

2020-07-13

Completion date

2023-12-31

Last updated

2023-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lyme Borreliosis

Keywords

Lyme borreliosis, Lyme neuroborreliosis, Bannwarth syndrome, Intrathecal CXCL-13

Brief summary

Neuroborreliosis (NBL) is diagnosed in 10-15% of patients with Lyme borreliosis. In Europe in adults, the main clinical manifestation is called Bannwarth syndrome. This includes painful meningoradiculitis, sometimes accompanied by cranial nerve neuritis. Current European guidelines issued by the European Federation of Neurological Societies (EFNS) recommend the following triad for the diagnosis of definite NBL: (i) Neurological symptoms suggestive of NBL without any other obvious cause; (ii) CSF pleocytosis; (iii) Intrathecal production of specific anti-Borreliella antibodies. CXCL13, C-X-C chemokine motif ligand 13, is a chemokine implicated in B cell chemotaxis. Extensive literature exists on the analysis of CXCL13i as a diagnostic marker for acute NBL. A recent meta-analysis from 2018, published by Rupprecht et al finds an overall sensitivity and specificity of 89% and 96% respectively, indicating satisfactory diagnostic value. In this study, the investigators wish to assess the place of this new marker in the diagnosis of neuroborreliosis before proposing it as a test carried out by the Borrelia CNR.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Major subject (≥18 years old) * Subject having consulted at the HUS between 01/01/2013 and 31/12/2018 * Subject not having, after being informed, expressed their opposition to the reuse of their data for the purposes of this research

Exclusion criteria

* Subject who expressed their opposition to participating in the study * Subject under guardianship or curatorship * Subject under safeguard of justice

Design outcomes

Primary

Measure	Time frame
Positivity of the marker (CXCL13-intrathecal) for known cases of NBL and negativity of this one for known non-NBL cases	Files analysed retrospectively from January 01, 2013 to December 31, 2018 will be examined

Countries

France

Contacts

Primary ContactBenoit JAULHAC, MD, PhD

benoit.jaulhac@chru-strasbourg.fr33 3 69 55 14 52

Outcome results